ABL Bio Inc
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also … Read more
ABL Bio Inc (298380) - Net Assets
Latest net assets as of September 2025: ₩182.22 Billion KRW
Based on the latest financial reports, ABL Bio Inc (298380) has net assets worth ₩182.22 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩234.99 Billion) and total liabilities (₩52.77 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩182.22 Billion |
| % of Total Assets | 77.54% |
| Annual Growth Rate | N/A |
| 5-Year Change | 84.5% |
| 10-Year Change | N/A |
| Growth Volatility | 55.25 |
ABL Bio Inc - Net Assets Trend (2016–2024)
This chart illustrates how ABL Bio Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ABL Bio Inc (2016–2024)
The table below shows the annual net assets of ABL Bio Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩167.28 Billion | +125.81% |
| 2023-12-31 | ₩74.08 Billion | +6.57% |
| 2022-12-31 | ₩69.51 Billion | +24.24% |
| 2021-12-31 | ₩55.95 Billion | -38.29% |
| 2020-12-31 | ₩90.66 Billion | -31.32% |
| 2019-12-31 | ₩132.01 Billion | -15.90% |
| 2018-12-31 | ₩156.96 Billion | +282.61% |
| 2017-12-31 | ₩-85.96 Billion | -610.43% |
| 2016-12-31 | ₩-12.10 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to ABL Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38461938496000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩24.14 Billion | 14.43% |
| Other Components | ₩541.44 Billion | 323.68% |
| Total Equity | ₩167.28 Billion | 100.00% |
ABL Bio Inc Competitors by Market Cap
The table below lists competitors of ABL Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CSC Financial Co. Ltd
F:CS0
|
$5.32 Billion |
|
China XD Electric Co Ltd
SHG:601179
|
$5.32 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
$5.32 Billion |
|
Mohawk Industries Inc
NYSE:MHK
|
$5.32 Billion |
|
Balchem Corporation
NASDAQ:BCPC
|
$5.32 Billion |
|
LEG Immobilien SE
PINK:LEGIF
|
$5.31 Billion |
|
Federal Hme 6.55 Pf
OTCQB:FMCKI
|
$5.30 Billion |
|
Lithia Motors Inc
NYSE:LAD
|
$5.30 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ABL Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 74,079,110,490 to 167,279,783,240, a change of 93,200,672,750 (125.8%).
- Net loss of 55,529,347,890 reduced equity.
- Share repurchases of 145,857,142,570 reduced equity.
- New share issuances of 145,857,142,570 increased equity.
- Other factors increased equity by 148,730,020,640.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-55.53 Billion | -33.2% |
| Share Repurchases | ₩145.86 Billion | -87.19% |
| Share Issuances | ₩145.86 Billion | +87.19% |
| Other Changes | ₩148.73 Billion | +88.91% |
| Total Change | ₩- | 125.81% |
Book Value vs Market Value Analysis
This analysis compares ABL Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 55.13x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩-627.24 | ₩191000.00 | x |
| 2017-12-31 | ₩-4456.10 | ₩191000.00 | x |
| 2018-12-31 | ₩3520.36 | ₩191000.00 | x |
| 2019-12-31 | ₩2913.87 | ₩191000.00 | x |
| 2020-12-31 | ₩1960.48 | ₩191000.00 | x |
| 2021-12-31 | ₩1187.37 | ₩191000.00 | x |
| 2022-12-31 | ₩1458.59 | ₩191000.00 | x |
| 2023-12-31 | ₩1546.78 | ₩191000.00 | x |
| 2024-12-31 | ₩3464.65 | ₩191000.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ABL Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -33.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -166.24%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 1.39x
- Recent ROE (-33.20%) is below the historical average (-30.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-12.47 Billion |
| 2017 | 0.00% | -104628.08% | 0.00x | 0.00x | ₩-66.14 Billion |
| 2018 | -74.69% | -9319.95% | 0.01x | 1.08x | ₩-132.93 Billion |
| 2019 | -28.03% | -927.68% | 0.03x | 1.08x | ₩-50.21 Billion |
| 2020 | -61.33% | -686.14% | 0.08x | 1.10x | ₩-64.67 Billion |
| 2021 | -77.85% | -816.91% | 0.08x | 1.17x | ₩-49.15 Billion |
| 2022 | 4.62% | 4.77% | 0.36x | 2.66x | ₩-3.74 Billion |
| 2023 | -3.57% | -4.04% | 0.41x | 2.16x | ₩-10.05 Billion |
| 2024 | -33.20% | -166.24% | 0.14x | 1.39x | ₩-72.26 Billion |
Industry Comparison
This section compares ABL Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ABL Bio Inc (298380) | ₩182.22 Billion | 0.00% | 0.29x | $5.32 Billion |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |